MAP2K1 and amyotrophic lateral sclerosis: There are no known completed or ongoing trials for the use of BRAFi in ALS, although a clinical trial for trametinib, a MEK1/MEK2 inhibitor which is downstream of BRAF, was recently completed (NCT04326283), although outcomes are yet to be reported.